Launch of Optimer®-Fc as a new reagent solution for immunohistochemistry Appointment of Chief Financial Officer Aptamer Group partner with BaseCure Therapeutics to develop new targeted gene therapies Aptamer Group signs two substantial new contracts Appointment of Interim Chief Commercial Officer Aptamer Group announce new deals to support novel therapies and improved assays Baroness Greenfield opens Aptamer Group’s new state-of-the-art laboratories Aptamer Group enters next stage of development within York Science Park Aptamer Group signs deal with Flip Gene Therapeutics to support the development of inducible gene therapies Aptamer Group and PinotBio extend collaboration for the development of Optimer-drug conjugates Honorary Professorship for Aptamer Group CEO Optimer-enabled wastewater monitoring system installed in UK networks Optimer® diagnostic reagent detects omicron variant Aptamer Group and ValitaCell to develop biomanufacturing screening platform Aptamer Group and DeepVerge expand partnership for Optimer-enabled wastewater monitoring Aptamer Group signs material commercial agreement with a life science research company Aptamer Group and BizCom announce collaboration for Optimer distribution and marketing services in Japan Aptamer Group and Bio-Works Technologies partner to enable improved solutions for gene therapy manufacturing Aptamer Group and ProAxsis Limited enter partnership to improve global logistics and stability of diagnostic tests Aptamer Group signs large commercial agreement with a public life science research company Aptamer Group and WuXi AppTec Research Service Division collaborate to identify new Optimer enabled therapeutics Aptamer Group partners with top five global pharmaceutical company to support innovative vaccine development Aptamer Group and PinotBio collaborate to develop new therapeutic drug conjugates Aptamer Group collaborates with world-leading pharmaceutical company to evaluate Optimer technology Aptamer Group extends collaboration with leading biopharmaceutical company to explore next-generation drug delivery approaches Aptamer Group makes progress in 2020 Aptamer Group advances COVID-19 testing capabilities with Integumen MP praises Aptamer Group’s COVID-19 work Aptamer Group attracts top talent to its scientific team Aptamer Group and Cytiva form new collaboration for the development of COVID-19 Rapid Test Integumen signs MTA with Aptamer Group Ltd Aptamer Group making headlines on their Point of Care COVID-19 reagent developments Aptamer Group and Valitacell announce partnership to build new drug discovery platform Aptamer Therapeutics and Cancer Research UK announce partnership for drug development programme Aptamer Group Announces Agreement with AstraZeneca to Explore Next-Generation Drug Delivery Devices Expansion plans to support Aptamer Group growth Aptamer Group Secures $2.2m Series A Investment
News
Start your next project with Aptamer Group
Contact one of our experts today Windmill House, Innovation Way, York, YO10 5BR, UK
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Manage consent
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.